ABBVIE INC. (ABBV) trades on NYSE and is classified in the Technology sector. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio. This page tracks ABBV using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$255.00
Volume
4,308,856.466
52-week range
$190.75 – $267.47
Market cap
$454.36B
Source: Polygon (daily close) · Verified Sep 11, 2026, 12:00 AM EDT
1D
+0.83%
1W
+0.26%
1M
+3.36%
1Y
+16.76%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Revenue (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue growth (YoY)
Reported Q2'26 · Polygon (company financials)
EPS (TTM, diluted)
Reported Q2'26 · Polygon (company financials)
EPS growth (YoY)
Reported Q2'26 · Polygon (company financials)
Gross margin
Reported Q2'26 · Polygon (company financials)
Operating margin
Reported Q2'26 · Polygon (company financials)
Net margin
Reported Q2'26 · Polygon (company financials)
Operating cash flow (TTM)
Reported Q2'26 · Polygon (company financials)
Revenue 2-year CAGR
Reported Q2'26 · Polygon (company financials)
Source: Polygon financials + Finnhub earnings · Latest reported Q2'26 · Verified Aug 2, 2026, 8:00 PM EDT
P/E (trailing)
Reported Q2'26 · Ticker-Terminal (last verified price ÷ TTM diluted EPS)
P/E (forward, est.)
Ticker-Terminal (last verified price ÷ annualised consensus EPS estimate)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Next earnings date
Oct 28, 2026
Source: Finnhub earnings calendar
Latest reported quarter
Q2'26
Revenue $16.99B · Diluted EPS 2.03
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | 3.65 | 3.68 | -0.7% |
| 2026-03-31 | 2.65 | 2.65 | +0.2% |
| 2025-12-31 | 2.71 | 2.71 | +0.2% |
| 2025-09-30 | 1.86 | 1.81 | +2.7% |
Analysis paused: current market inputs are not fresh enough to update it.
Analysis paused: current market inputs are not fresh enough to update it.
Rating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
39
Source: finnhub
The Motley Fool · Sep 13, 2026
Zacks Investment Research · Sep 11, 2026
Zacks Investment Research · Sep 11, 2026
The Motley Fool · Sep 10, 2026
The Motley Fool · Sep 9, 2026
GlobeNewswire Inc. · Sep 8, 2026
Some data is delayed, stale or unavailable. Everything shown is still verified.
Company profile and business overview · Reported financial statements · Earnings history
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
ABBVIE INC. trades under the ticker ABBV on NYSE.
ABBV was last verified at $257.12 (0.83% on the day). Pre-market, last verified Sep 11, 2026, 12:00 AM EDT. Market data may be delayed and is shown with its own timestamp.
Based on the latest reported financials, ABBV revenue changed 10.2% year over year (filed Aug 2, 2026).
The next confirmed ABBV earnings date is Oct 28, 2026, per Finnhub earnings calendar. Dates can be revised by the company.
For Q2'26, ABBV reported revenue of $16.99B and diluted EPS of 2.03.
Create a free Ticker-Terminal account to run a full AI research report on ABBV — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Free guide series
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from ABBV's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Sep 14, 2026, 4:08 AM EDT.